EUVIMEDEUVIMED entdecken
Open Access

Trends in Medical Management of Moderately to Severely Active Ulcerative Colitis: A Nationwide Retrospective Analysis

William Yuan iD, Jayson S Marwaha, Shana T Rakowsky, Nathan P Palmer, Isaac S Kohane, David T Rubin, Gabriel A Brat, Joseph D Feuerstein

Inflammatory Bowel Diseases · 02.05.2023 · 29 (5) · 695-704

DOI: 10.1093/ibd/izac134 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 04.07.2022. Verfasst von William Yuan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Biological Products. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NIH HHS, National Institute of Child and Human Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

With an increasing number of therapeutic options available for the management of ulcerative colitis (UC), the variability in treatment and prescribing patterns is not well known. While recent guidelines have provided updates on how these therapeutic options should be used, patterns of long-term use of these drugs over the past 2 decades remain unclear.

Methods

We analyzed a retrospective, nationwide cohort of more than 1.7 million prescriptions for trends in prescribing behaviors and to evaluate practices suggested in guidelines relating to ordering biologics, step-up therapy, and combination therapy. The primary outcome was 30-day steroid-free remission and secondary outcomes included hospitalization, cost, and additional steroid usage. A pipeline was created to identify cohorts of patients under active UC medical management grouped by prescribing strategies to evaluate comparative outcomes between strategies. Cox proportional hazards and multivariate regression models were utilized to assess postexposure outcomes and adjust for confounders.

Results

Among 6 major drug categories, we noted major baseline differences in patient characteristics at first exposure corresponding to disease activity. We noted earlier use of biologics in patient trajectories (762 days earlier relative to UC diagnosis, 2018 vs 2008; P < .001) and greater overall use of biologics over time (2.53× more in 2018 vs 2008; P < .00001) . Among biologic-naive patients, adalimumab was associated with slightly lower rates of remission compared with infliximab or vedolizumab (odds ratio, 0.92; P < .005). Comparisons of patients with early biologic initiation to patients who transitioned to biologics from 5-aminosalicylic acid suggest lower steroid consumption for early biologic initiation (-761 mg prednisone; P < .001). Combination thiopurine-biologic therapy was associated with higher odds of remission compared with biologic monotherapy (odds ratio, 1.36; P = .01).

Conclusions

As biologic drugs have become increasingly available for UC management, they have increasingly been used at earlier stages of disease management. Large-scale analyses of prescribing behaviors provide evidence supporting early use of biologics compared with step-up therapy and use of thiopurine and biologic combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeBiological ProductsHumansRetrospective StudiesInfliximabAdalimumabBiological FactorsImmunologic Factors

Stichwörter der Autor:innen

biologicprescriptionretrospective analysistrendsulcerative colitis

Substanzen

InfliximabAdalimumabBiological FactorsImmunologic FactorsBiological Products

Autor:innen und Institutionen

  • Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
  • Computational Health Informatics Program, Boston Children's Hospital, Boston, MA, USA.
  • Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medicine, Chicago, IL, USA.
  • Division of Gastroenterology and Center for Inflammatory Bowel Diseases, Beth Israel Deaconess Medical Center, Boston, MA, USA.

ORCID-Profile: William Yuan

Förderung

  • NICHD NIH HHS
  • NIH HHS
  • National Institute of Child and Human Development
  • National Institutes of Health
  • Harvard Medical School

Zitieren

APA

Yuan, W., Marwaha, J. S., Rakowsky, S. T., Palmer, N. P., Kohane, I. S., Rubin, D. T., Brat, G. A., & Feuerstein, J. D. (2023). Trends in Medical Management of Moderately to Severely Active Ulcerative Colitis: A Nationwide Retrospective Analysis. Inflammatory Bowel Diseases, 29(5), 695-704. https://doi.org/10.1093/ibd/izac134

Vancouver

Yuan W, Marwaha JS, Rakowsky ST, Palmer NP, Kohane IS, Rubin DT, et al. Trends in Medical Management of Moderately to Severely Active Ulcerative Colitis: A Nationwide Retrospective Analysis. Inflammatory Bowel Diseases. 2023;29(5):695-704. doi:10.1093/ibd/izac134

BibTeX
@article{Yuan2023,
  author = {Yuan, William and Marwaha, Jayson S and Rakowsky, Shana T and Palmer, Nathan P and Kohane, Isaac S and Rubin, David T and Brat, Gabriel A and Feuerstein, Joseph D},
  title = {Trends in Medical Management of Moderately to Severely Active Ulcerative Colitis: A Nationwide Retrospective Analysis},
  journal = {Inflammatory Bowel Diseases},
  year = {2023},
  volume = {29},
  number = {5},
  pages = {695--704},
  doi = {10.1093/ibd/izac134}
}
Kostenlos starten →